Construction of Self-management Scheme for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068340

Enrollment

Unknown

Registered

2023-02-15

Start date

2023-02-08

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Observation group:none

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1: Female, =18 years old 2: Diagnosed as breast cancer by clinical and pathological diagnosis 3: During the chemotherapy cycle, neurotoxic chemotherapy drugs (such as paclitaxel, docetaxel, etc.) are used 4: Clear awareness, informed consent and voluntary participation in this study

Exclusion criteria

Exclusion criteria: 1: Complicated with other tumors or severe liver and kidney damage 2: Peripheral neuropathy combined with other causes (such as diabetes, thyroid insufficiency, etc.)

Design outcomes

Primary

Measure	Time frame
Functional Assessment of Cancer Therapy/ Gynaecologic Oncology Group Neurotoxicity, FACT/GOG-Ntx;	—

Secondary

Measure	Time frame
Patient Activation Measure (PAM);Cancer Patient Self-management Assessment Scale;	—

Countries

China

Contacts

Public ContactShi Tieying

The First Affiliated Hospital of Dalian Medical University

1980260439@qq.com18098871912

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026